On June 13, 2023, Zynerba Pharmaceuticals, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting. Pursuant to the Company’s Amended and Restated Bylaws, the Company’s stockholders approved an adjournment of the Annual Meeting to 9:00 A.M. EDT on June 28, 2023 to allow additional time for stockholders to vote on Proposal 2.

(a) Proposal 1 — Election of Seven Directors. Each director nominee was elected to the Board of Directors of the Company to serve as a director until the 2024 Annual Meeting of Stockholders of the Company or until his or her respective successor is elected and qualified. The results of the votes cast were as follows:

(b) Proposal 2 — Approval of Amendment to the Sixth Amended and Restated Certificate of Incorporation of the Company. As noted above, the Company adjourned the Annual Meeting solely with respect to Proposal 2 to allow additional time for stockholders to consider and vote on Proposal 2. At the adjourned meeting, only Proposal 2 will be presented for stockholder consideration.

(c) Proposal 3 — Ratification of Independent Registered Public Accountant. The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was ratified. The results of the votes cast were as follows:

(d) Proposal 4 — Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers. The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executed officers. The results of the votes cast were as follows:

(e) Proposal 5 — Approval of the Zynerba Pharmaceuticals, Inc. 2023 Stock Option and Incentive Plan. The Company’s stockholders approved the Zynerba Pharmaceuticals, Inc. 2023 Stock Option and Incentive Plan. The results of the votes cast were as follows:

(f) Proposal 6 — Approval, for purposes of complying with applicable Nasdaq Listing Rules, of the potential issuance and sale of 20% or more of the Company’s common stock pursuant to the Purchase Agreement with Lincoln Park Capital Fund, LLC. The Company’s stockholders approved the potential issuance and sale of 20% or more of the Company’s common stock pursuant to the Purchase Agreement with Lincoln Park Capital Fund, LLC. The results of the votes cast were as follows:

(g) Proposal 7 — Approval of the adjournment of the Annual Meeting to a later date to permit further solicitation of additional proxies in the event there are insufficient votes to approve Proposal 2. The Company’s stockholders approved the adjournment of the Annual Meeting solely with respect to Proposal 2. The results of the votes cast were as follows:

Accordingly, the Annual Meeting was adjourned to 9:00 A.M. EDT on June 28, 2023 in the same virtual format described in the Definitive Proxy Statement. Only stockholders of record as of April 17, 2023, the record date for the Annual Meeting, are entitled to vote at the reconvened Annual Meeting. Proxies previously submitted with respect to Proposal 2 will be voted at the reconvened Annual Meeting unless properly revoked; stockholders who have previously submitted their proxy or otherwise voted with respect to Proposal 2 and who do not want to change their vote need not take any action.